Martin Borch Jensen, PhD, works broadly to industrialize longevity. He is Co-founder and Chief Scientific Officer of Gordian Biotechnology, the first company to discover novel therapeutic targets for complex diseases through pooled in vivo screening. He led the development of the technology, and the creation of intervention-response atlases in living diseased tissue, at a scale usually only possible in cell culture. In addition to his work at Gordian, Martin is founder and president of Norn Group, a “do tank” addressing other bottlenecks to a mature longevity industry. Norn runs talent and immigration programs to expand the talent pool, has awarded >150 Impetus Grants to high-risk research, supports government and regulatory initiatives, and builds programs to remove bottlenecks to research and drug development for longer lives.